

Professor John Bartlett is currently the Director of Transformative Pathology at the Ontario Institute for Cancer Research in Toronto Canada. Following training as a Biochemist and Reproductive Endocrinologist Professor Bartlett switched to translational cancer research in 1990. During his time at Glasgow and Edinburgh Universities (1993-2011) John built an international reputation as a translational research scientist, which lead to the award of a Fellowship of the Royal College of Pathologists and a Personal Chair at Edinburgh University. During this time he also developed the UK NEQAS

scheme for HER2 ISH testing and was responsible for a number of key publications in the field. Having recently moved to Toronto, Professor Bartlett has now published over 150 research articles and is co-author on the UK guidelines for HER2 testing.